Kidney Failure Clinical Trial
— VAVASCOfficial title:
Validation of Arterio Venous Access Stage Classification by Using Machine Learning in Prediction of Vascular Access Creation and Uninterrupted Use of the Vascular Access for Dialysis
VAVASC trial is an observational multicentre study. The aim of this trial is to validate AVAS (arteriovenous vascular access stage) classification. The classification is used for determining which type of access is the most suitable for the patient on the basis of the patient´s vascular anatomy The methodology of this trial is to apply AVAS classification on patients who are indicated for creation of vascular access for hemodialysis. Data on these patients (vascular anatomy status, AVAS type, and predicted type of arterio venous access, demographic data etc.) will be than statistically analysed. Patients will then undergo creation of the selected arteriovenous access. They will be observed in terms of the access functionality. The follow up will be 1 to 3 years. The second aim of this study is to evaluate the relationship between AVAS classification and uninterrupted use of the created arterio venous access.
Status | Active, not recruiting |
Enrollment | 800 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria: - patients indicated for creation of arterio venous access for dialysis Exclusion Criteria: - patients who disagree to participate in the study |
Country | Name | City | State |
---|---|---|---|
Czechia | Vascular surgery, University hospital Královské Vinohrady | Prague |
Lead Sponsor | Collaborator |
---|---|
Vascular surgery, University hospital Královské Vinohrady, Prague | Belfast Health and Social Care Trust |
Czechia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Arterio Venous Access Stage (AVAS) evaluation | What type of the Arterio Venous Access Stage (AVAS classification) the patient has based on his/her vascular anatomy of upper limbs | Baseline - recruiting (Year 1) - physical examination, data collection and evaluation of Arterio Venous Access Stage (AVAS) | |
Primary | Arterio Venous Access type predicted | What type of the Arterio Venous Access is predicted based on AVAS and other clinical factors | Baseline - recruiting (Year 1) - physical examination, data collection and evaluation of Arterio Venous Access Stage (AVAS) and predicting a type of arterio venous access | |
Primary | Final Arterio Venous Access | What type of the arterio venous access was eventually created (in corelation with AVAS evaluation and the predicted arteriovenous access type) | Follow up (up to 1-2 years) what type of arterio venous access was eventually created | |
Primary | Functionality of the arterio venous access | Uninterrupted use of the created arterio venous access | Year 2-3 - follow up, collection the data about the functionality (uninterrupted use) of the arterio venous access and evaluation of the relation between AVAS and the functionality of the arterio venous access |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04510090 -
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
|
Phase 1 | |
Completed |
NCT02546037 -
Clotting With Different Dialyzer Membranes
|
||
Recruiting |
NCT02545920 -
To Assess Ear Blood Flow During Dialysis
|
||
Completed |
NCT02134314 -
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
|
Phase 1/Phase 2 | |
Recruiting |
NCT01912001 -
Virtual Ward for Home Dialysis
|
N/A | |
Completed |
NCT01158742 -
Live Kidney Donor Study -Renal Function Study
|
N/A | |
Completed |
NCT00986947 -
Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates
|
Phase 2 | |
Completed |
NCT00765661 -
Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients
|
Phase 2 | |
Withdrawn |
NCT00807274 -
Renal Function in Adults With Congenital Heart Disease.
|
N/A | |
Completed |
NCT00369382 -
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
|
Phase 4 | |
Completed |
NCT00183248 -
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT05324878 -
Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis
|
||
Completed |
NCT05272800 -
BIS-guided Fluid Management in HD Patients
|
N/A | |
Completed |
NCT03836508 -
Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis
|
N/A | |
Completed |
NCT01756508 -
Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury
|
Phase 2 | |
Completed |
NCT03723668 -
Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France
|
||
Recruiting |
NCT04277377 -
Nanoparticle for DSA Removal
|
||
Terminated |
NCT00450333 -
Dynepo Infrequent Dosing Study
|
Phase 3 | |
Terminated |
NCT03840343 -
Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
|
Phase 1 | |
Recruiting |
NCT04714853 -
Different Dialysis Modalities and Diet on Gastrointestinal Biome and Azotaemic Toxins
|